x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230673
| Product Information | |
|---|---|
| CAS No. | 127191-97-3 |
| Formula | C38H35N5O6S2 |
| Molecular Weight | 721.84 |
| SMILES | CN(C(CC1=CC=C(O[S](=O)(=O)C2=C3C=CN=CC3=CC=C2)C=C1)C(=O)N4CCN(CC4)C5=CC=CC=C5)[S](=O)(=O)C6=CC=CC7=C6C=CN=C7 |
| Target | Ca2+/calmodulin-dependent protein kinase II (CaMKII) |
| Product Description | KN-62 is a potent and specific inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII) with Ki of 0.9 μM also a non-competitive antagonist of the purinergic receptor P2RX7 (IC50 = 15 nM). It is selective for CaMKII relative to PKA, PKC and MLCK, but inhibits CaMKI and CaMKIV equally well, The Ki value of KN-62 for CaMK V is 0.8 μM. |
| Format & Storage | |
|---|---|
| Purity | > 99% |
| Shipping | Shipped on dry ice. |
| Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
